Tarsa Therapeutics
Philadelphia
About Tarsa Therapeutics
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $124.2M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Jul 2016)
- Website: tarsatherapeutics.com
- Phone: 267-273-7940
Industries & Categories
Biotechnology, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/tarsa-therapeutics-194046 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.